Invex Therapeutics' (ASX: IXC) new partnership de-risks Presendin development (w/ Thomas Duthy)

Invex Therapeutics (ASX: IXC) executive director Thomas Duthy joins Small Caps to discuss the company’s new partnership with Korean biopharmaceutical company Peptron. The pair have signed an exclusive collaboration and manufacturing agreement that is expected to de-risk the development of Invex’s lead drug Presendin for the treatment of idiopathic intracranial hypertension (IIH). The deal will grant Invex access to drug product, extensive data and Peptron’s manufacturing and technical expertise, enabling it to bypass required activities saving both money and time in Presendin’s development pathway.Article:https://smallcaps.com.au/invex-therapeutics-signs-major-collaboration-with-peptron/For more information:https://smallcaps.com.au/stocks/IXC/See omnystudio.com/listener for privacy information.